These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 28512248)

  • 1. Androgen Receptor Supports an Anchorage-Independent, Cancer Stem Cell-like Population in Triple-Negative Breast Cancer.
    Barton VN; Christenson JL; Gordon MA; Greene LI; Rogers TJ; Butterfield K; Babbs B; Spoelstra NS; D'Amato NC; Elias A; Richer JK
    Cancer Res; 2017 Jul; 77(13):3455-3466. PubMed ID: 28512248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple molecular subtypes of triple-negative breast cancer critically rely on androgen receptor and respond to enzalutamide in vivo.
    Barton VN; D'Amato NC; Gordon MA; Lind HT; Spoelstra NS; Babbs BL; Heinz RE; Elias A; Jedlicka P; Jacobsen BM; Richer JK
    Mol Cancer Ther; 2015 Mar; 14(3):769-78. PubMed ID: 25713333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional characterization of androgen receptor in two patient-derived xenograft models of triple negative breast cancer.
    Wang X; Petrossian K; Huang MJ; Saeki K; Kanaya N; Chang G; Somlo G; Chen S
    J Steroid Biochem Mol Biol; 2021 Feb; 206():105791. PubMed ID: 33271252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer Cells.
    Michmerhuizen AR; Chandler B; Olsen E; Wilder-Romans K; Moubadder L; Liu M; Pesch AM; Zhang A; Ritter C; Ward ST; Santola A; Nyati S; Rae JM; Hayes D; Feng FY; Spratt D; Wahl D; Eisner J; Pierce LJ; Speers C
    Front Endocrinol (Lausanne); 2020; 11():35. PubMed ID: 32117061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estrogen receptor beta increases sensitivity to enzalutamide in androgen receptor-positive triple-negative breast cancer.
    Anestis A; Sarantis P; Theocharis S; Zoi I; Tryfonopoulos D; Korogiannos A; Koumarianou A; Xingi E; Thomaidou D; Kontos M; Papavassiliou AG; Karamouzis MV
    J Cancer Res Clin Oncol; 2019 May; 145(5):1221-1233. PubMed ID: 30805773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts.
    Coussy F; Lavigne M; de Koning L; Botty RE; Nemati F; Naguez A; Bataillon G; Ouine B; Dahmani A; Montaudon E; Painsec P; Chateau-Joubert S; Laetitia F; Larcher T; Vacher S; Chemlali W; Briaux A; Melaabi S; Salomon AV; Guinebretiere JM; Bieche I; Marangoni E
    Theranostics; 2020; 10(4):1531-1543. PubMed ID: 32042320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical evaluation of the AR inhibitor enzalutamide in triple-negative breast cancer cells.
    Caiazza F; Murray A; Madden SF; Synnott NC; Ryan EJ; O'Donovan N; Crown J; Duffy MJ
    Endocr Relat Cancer; 2016 Apr; 23(4):323-34. PubMed ID: 26932782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ceritinib is a novel triple negative breast cancer therapeutic agent.
    Dong S; Yousefi H; Savage IV; Okpechi SC; Wright MK; Matossian MD; Collins-Burow BM; Burow ME; Alahari SK
    Mol Cancer; 2022 Jun; 21(1):138. PubMed ID: 35768871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen deprivation therapy sensitizes triple negative breast cancer cells to immune-mediated lysis through androgen receptor independent modulation of osteoprotegerin.
    Kwilas AR; Ardiani A; Gameiro SR; Richards J; Hall AB; Hodge JW
    Oncotarget; 2016 Apr; 7(17):23498-511. PubMed ID: 27015557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer.
    Thakkar A; Wang B; Picon-Ruiz M; Buchwald P; Ince TA
    Breast Cancer Res Treat; 2016 May; 157(1):77-90. PubMed ID: 27120467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RUNX1 Is Regulated by Androgen Receptor to Promote Cancer Stem Markers and Chemotherapy Resistance in Triple Negative Breast Cancer.
    Fernández NB; Sosa SM; Roberts JT; Recouvreux MS; Rocha-Viegas L; Christenson JL; Spoelstra NS; Couto FL; Raimondi AR; Richer JK; Rubinstein N
    Cells; 2023 Jan; 12(3):. PubMed ID: 36766786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer.
    Ring A; Kaur P; Lang JE
    BMC Cancer; 2020 Nov; 20(1):1076. PubMed ID: 33167919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of palbociclib with enzalutamide shows in vitro activity in RB proficient and androgen receptor positive triple negative breast cancer cells.
    Liu CY; Lau KY; Hsu CC; Chen JL; Lee CH; Huang TT; Chen YT; Huang CT; Lin PH; Tseng LM
    PLoS One; 2017; 12(12):e0189007. PubMed ID: 29261702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of the androgen receptor in triple-negative breast cancer.
    Rampurwala M; Wisinski KB; O'Regan R
    Clin Adv Hematol Oncol; 2016 Mar; 14(3):186-93. PubMed ID: 27058032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Positive Feedback Loop Between TGFβ and Androgen Receptor Supports Triple-negative Breast Cancer Anoikis Resistance.
    Rosas E; Roberts JT; O'Neill KI; Christenson JL; Williams MM; Hanamura T; Spoelstra NS; Vahrenkamp JM; Gertz J; Richer JK
    Endocrinology; 2021 Feb; 162(2):. PubMed ID: 33294922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease.
    Barton VN; D'Amato NC; Gordon MA; Christenson JL; Elias A; Richer JK
    Horm Cancer; 2015 Dec; 6(5-6):206-13. PubMed ID: 26201402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiproliferative Effect of Androgen Receptor Inhibition in Mesenchymal Stem-Like Triple-Negative Breast Cancer.
    Zhu A; Li Y; Song W; Xu Y; Yang F; Zhang W; Yin Y; Guan X
    Cell Physiol Biochem; 2016; 38(3):1003-14. PubMed ID: 26938985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ERβ1 inhibits metastasis of androgen receptor-positive triple-negative breast cancer by suppressing ZEB1.
    Song W; Tang L; Xu Y; Sun Q; Yang F; Guan X
    J Exp Clin Cancer Res; 2017 Jun; 36(1):75. PubMed ID: 28583190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Receptors for Insulin-Like Growth Factor-2 and Androgens as Therapeutic Targets in Triple-Negative Breast Cancer.
    Hamilton N; Austin D; Márquez-Garbán D; Sanchez R; Chau B; Foos K; Wu Y; Vadgama J; Pietras R
    Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29099049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective androgen receptor modulators (SARMs) negatively regulate triple-negative breast cancer growth and epithelial:mesenchymal stem cell signaling.
    Narayanan R; Ahn S; Cheney MD; Yepuru M; Miller DD; Steiner MS; Dalton JT
    PLoS One; 2014; 9(7):e103202. PubMed ID: 25072326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.